Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2021

View Archived Issues

TATX-03 PolyTope monoclonal antibody cocktail shows efficacy in hamster model of COVID-19

Tumor neoantigens can inhibit immune response

Perception Neuroscience reports first phase I data on PCN-101

Enzyme controlling neural stem cell proliferation identified

EMT drives zebrafish spinal cord repair

Promising new data from phase II advanced liver cancer study of namodenoson

Cartesian initiates phase IIa study of Descartes-11 for multiple myeloma

AstraZeneca announces voluntary withdrawal of Imfinzi in advanced bladder cancer in the U.S.

Griffith University patents new viral hemagglutinin and/or neuraminidase inhibitors

Shanghai Zhimeng Biopharma discloses HBsAg secretion inhibitors

Zhuhai Yufan Biotechnologies presents new IRAK-4 inhibitors

Bayer AG synthesizes new compounds for helminthic infections

Cassava Sciences outlines pivotal phase III program for simufilam in Alzheimer's disease

Ascentage Pharma discovers BCR-ABL1 kinase inhibitors

FDA grants clearance to proceed with clinical testing of tempol as treatment of COVID-19

Opioid vaccines elicit antibodies against carfentanil and fentanyl

Neutralizing activity of tozinameran-elicited serum against the B.1.351 lineage of SARS-CoV-2

NGF-loaded biodegradable microcapsules show morphogenic effects on hippocampal neuron cultures

U-ACCOMPLISH induction study of upadacitinib meets primary and all ranked secondary endpoints

Orexin 1 receptor might be a therapeutic target in PTSD-related psychosis

Pharmaxis initiates phase I/IIa study of PXS-5505 in myelofibrosis

Libtayo approved in U.S. for first-line NSCLC with PD-L1 expression >=50%

Targovax reports 21-month follow-up data from phase I/II trial of ONCOS-102 in MPM

Phase II data on daxibotulinumtoxin A in upper limb spasticity support program progression

Celldex plans clinical study of CDX-0159 in prurigo nodularis

Dosing begins in first-in-human study of LG-00303174 for NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...